骨质疏松治疗多肽药物综述
樊亚萍 马建苹

兰州理工大学，甘肃兰州，730000；

摘要：骨质疏松是由多种因素引发的全身性骨骼疾病，其特征表现为骨密度降低、骨微结构破坏及骨脆性增加。目前，该疾病治疗药物以骨形成促进剂、骨吸收抑制剂及骨代谢调节剂为主，大多为小分子化合物。然而，随着生物医药科技的进步，多种多肽类药物已被研发出来。与传统药物相比，多肽类药物显示出靶向特异性强、作用机制清晰、疗效高且毒性低等特点，能够实现个体化治疗，为患者群体提供更多治疗选择。本文通过对治疗骨质疏松症的多肽类药物进行系统综述，以期为临床医生在治疗骨质疏松症时提供科学依据和参考信息。

关键字：骨质疏松；多肽药物；特立帕肽；阿巴帕肽；降钙素；骨形态发生蛋白

参考文献

[1]Kundu B, Khare S K, Singh G. Role of polypeptides in the treatment and diagnosis of osteoporosis [J]. Peptides, 1999,20(4): 523-537.

[2]苏欣, 廖二元. 甲状旁腺激素及其拟似剂治疗骨质疏松症的研究进展 [J]. 国际内科学杂志, 2007(11): 645-648.

[3]Tam C S, Heersche J N, Murray T M, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration [J]. Endocrinology, 1982,110(2): 506-512.

[4]Abdulelah A A, Haddad B I, Alhajahjeh A A, et al. The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review [J]. Orthop Res Rev, 2023,15: 191-198.

[5]Vahle J L, Long G G, Sandusky G, et al. Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose [J]. Toxicologic Pathology, 2004,32(4): 426-438.

[6]Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34) [J]. Regul Toxicol Pharmacol, 2017,86: 356-365.

[7]Qaseem A, Snow V, Shekelle P, et al. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians [J]. Annals of Internal Medicine, 2008,149(6): 404-415.

[8]Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin [J]. Exp Clin Endocrinol Diabetes, 1995,103(6): 345-351.

[9]Gennari C, Agnusdei D, Camporeale A. Long-term treatment with calcitonin in osteoporosis [J]. Horm Metab Res, 1993,25(9): 484-485.

[10]Wei F L, Gao Q Y, Zhu K L, et al. Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women [J]. Heliyon, 2023,9(2): e11880.

[11]Nakase T, Yoshikawa H. Potential roles of bone morphogenetic proteins (BMPs) in skeletal repair and regeneration [J]. J Bone Miner Metab, 2006,24(6): 425-433.

[12]段智霞, 郑启新, 郭晓东, et al. BMP-2活性多肽体外定向诱导大鼠BMSCs向成骨方向分化的实验研究 [J]. 中国矫形外科杂志, 2007,15(21): 4.

[13]Ouyang X, Ding Y, Yu L, et al. Effects of BMP-2 compound with fibrin on osteoporotic vertebral fracture healing in rats [J]. J Musculoskelet Neuronal Interact, 2021,21(1): 149-156.

[14]Love S A, Gultian K A, Jalloh U S, et al. Mesenchymal stem cells enhance targeted bone growth from injectable hydrogels with BMP-2 peptides [J]. J Orthop Res, 2024,42(7): 1599-1607.